Cardiac Imaging in the VALOR-HCM Trial

Cardiac Consult: A Cleveland Clinic Podcast for Healthcare Professionals - A podcast by Cleveland Clinic Heart & Vascular Institute - Thursdays

Mavacamten is the first and only FDA-approved cardiac myosin inhibitor to treat obstructive hypertrophic cardiomyopathy (HCM). An important factor to the success of the VALOR HCM trial was the participation of specialized cardiac sonographers and imagers. Milind Desai, MD, MBA speaks with Jeanne Drinko, Amy Kanta and Anne Campbell about the importance of cardiac imaging. Learn more about C5 Research at Cleveland Clinic. https://my.clevelandclinic.org/research/c5research Looking to r...